FORGOT YOUR DETAILS?

Stallergenes and LINK are pleased to announce the reinforcement of their partnership for the Australian market. Stallergenes has recently created a dedicated Australian affiliate company to work alongside LINK, providing management, medical and marketing support to answer the specific needs of allergy clinicians and patients with allergies.

SYDNEY, NSW, OCTOBER 28, 2008. LINK Pharma, a specialist Australian-owned pharmaceutical company, is pleased to announce that the Anapen® adrenaline auto-injector has been approved for marketing in Australia. LINK has been working towards providing an alternative adrenaline auto-injector device for the many Australians who may be at risk of anaphylaxis. The registration of Anapen® in

LINK Pharmaceuticals today announced a second major acquisition for 2008 with the transfer of the former Novartis products Apresoline, Deseril and Hygroton. This transfer is an extension of LINK’s on-going partnership with the UK company Amdipharm. Amdipharm recently completed the acquisition of these products from Novartis for several international markets and LINK will market them

LINK Pharmaceuticals today announced the transfer of the Akineton, Erythocin IV and the EES (erythromycin) product range from Abbott Australia. This transfer is the result of LINK’s on-going partnership with the UK company Amdipharm. Amdipharm recently completed the acquisition of these products from Abbott for several international markets and LINK will market them in Australia

Zostrix on the Shelves

Sunday, 01 July 2007 by

On 1st July 2007 the big three pharmaceutical wholesalers took stock of both Zostrix and Zostrix HP. As a result retail pharmacies should have stock soon after that date. This is good news for those suffering the pain associate with osteoarthritis, diabetic neuropathy and post-herpetic neuralgia. ZOSTRIX is registered by the Australian authorities in two

Naprosyn Suspension Re-listed by PBS

Wednesday, 18 January 2006 by

On April 1st 2006 patients will have access to the liquid formulation of Naprosyn (naproxen) through the Pharmaceutical Benefits Scheme. This completes a two year joint project between LINK Pharmaceuticals and Roche Products to secure the long-term supply of this product in Australia for the treatment of chronic arthropathies and bone pain for patients unable

LINK Pharmaceuticals announces the acquisition of two antibiotic products from Pfizer for the territories of Australia and New Zealand. The two injectable products, colistin and chloramphenicol are both essential treatments for serious infections. While the use of chloramphenicol is now highly restrictive due to the high incidence of serious side effects, it still has an

TOP